Bioequivalence tests to be stimulated

Published: 2003-03-24 07:00:00

Updated: 2003-03-24 07:00:00

The Korea Food and Drug Administration said that in its business briefing to the minister of Health and Welfare on March 19, bioequivalence tests need to be further activated via withdrawal of ex post facto reporting to doctors after substitute drug dispensing and of such dispensing prior notice ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK